|
1
|
Stein IF and Leventhal ML: Amenorrhea
associated with bilateral polycystic ovaries. Am J Obstet Gynecol.
29:181–191. 1935. View Article : Google Scholar
|
|
2
|
Carmina E, Napoli N, Longo RA, Rini GB and
Lobo RA: Metabolic syndrome in polycystic ovary syndrome (PCOS):
Lower prevalence in southern Italy than in the USA and the
influence of criteria for the diagnosis of PCOS. Eur J Endocrinol.
154:141–145. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Broekmans FJ, Knauff EA, Valkenburg O,
Laven JS, Eijkemans MJ and Fauser BC: PCOS according to the
Rotterdam consensus criteria: Change in prevalence among WHO-II
anovulation and association with metabolic factors. BJOG.
113:1210–1217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Anagnostis P, Tarlatzis BC and Kauffman
RP: Polycystic ovarian syndrome (PCOS): Long-term metabolic
consequences. Metabolism. 86:33–43. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li Q, Du J, Feng R, Xu Y, Wang H, Sang Q,
Xing Q, Zhao X, Jin L, He L and Wang L: A possible new mechanism in
the pathophysiology of polycystic ovary syndrome (PCOS): The
discovery that leukocyte telomere length is strongly associated
with PCOS. J Clin Endocrinol Metab. 99:E234–E240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alanbay I, Ercan CM, Sakinci M, Coksuer H,
Ozturk M and Tapan S: A macrophage activation marker
chitotriosidase in women with PCOS: Does low-grade chronic
inflammation in PCOS relate to PCOS itself or obesity? Arch Gynecol
Obstet. 286:1065–1071. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ortega I, Villanueva JA, Wong DH, Cress
AB, Sokalska A, Stanley SD and Duleba AJ: Resveratrol potentiates
effects of simvastatin on inhibition of rat ovarian
theca-interstitial cells steroidogenesis. J Ovarian Res. 7:212014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noroozzadeh M, Behboudi-Gandevani S,
Zadeh-Vakili A and Ramezani Tehrani F: Hormone-induced rat model of
polycystic ovary syndrome: A systematic review. Life Sci.
191:259–272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bingham J, Sudarsanam S and Srinivasan S:
Profiling human phosphodiesterase genes and splice isoforms.
Biochem Biophys Res Commun. 350:25–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vezzosi D and Bertherat J:
Phosphodiesterases in endocrine physiology and disease. Eur J
Endocrinol. 165:177–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calverley PM, Rabe KF, Goehring UM,
Kristiansen S, Fabbri LM and Martinez FJ; M2-124 and M2-125 study
groups, . Roflumilast in symptomatic chronic obstructive pulmonary
disease: Two randomised clinical trials. Lancet. 374:685–694. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai LC and Beavo JA: The roles of cyclic
nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin
Pharmacol. 11:670–675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wouters EF, Bredenbröker D, Teichmann P,
Brose M, Rabe KF, Fabbri LM and Göke B: Effect of the
phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in
patients with treatment-naive, newly diagnosed type 2 diabetes
mellitus. J Clin Endocrinol Metab. 97:E1720–E1725. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jensterle M, Kocjan T and Janez A:
Phosphodiesterase 4 inhibition as a potential new therapeutic
target in obese women with polycystic ovary syndrome. J Clin
Endocrinol Metab. 99:E1476–E1481. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin P and Xie Y: Treatment strategies for
women with polycystic ovary syndrome. Gynecol Endocrinol.
34:272–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jensterle M, Salamun V, Kocjan T, Vrtacnik
Bokal E and Janez A: Short term monotherapy with GLP-1 receptor
agonist liraglutide or PDE 4 inhibitor roflumilast is superior to
metformin in weight loss in obese PCOS women: A pilot randomized
study. J Ovarian Res. 8:322015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Anderson E, Lee MT and Lee GY:
Cystogenesis of the ovarian antral follicle of the rat:
Ultrastructural changes and hormonal profile following the
administration of dehydroepiandrosterone. Anat Rec. 234:359–382.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mannerås L, Cajander S, Holmäng A,
Seleskovic Z, Lystig T, Lönn M and Stener-Victorin E: A new rat
model exhibiting both ovarian and metabolic characteristics of
polycystic ovary syndrome. Endocrinology. 148:3781–3791. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu XY, Li ZL, Wu CY, Liu YM, Lin H, Wang
SH and Xiao WF: Endocrine traits of polycystic ovary syndrome in
prenatally androgenized female Sprague-Dawley rats. Endocr J.
57:201–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sander V, Luchetti CG, Solano ME, Elia E,
Di Girolamo G, Gonzalez C and Motta AB: Role of the N,
N′-dimethylbiguanide metformin in the treatment of female
prepuberal BALB/c mice hyperandrogenized with
dehydroepiandrosterone. Reproduction. 131:591–602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reagan-Shaw S, Nihal M and Ahmad N: Dose
translation from animal to human studies revisited. FASEB J.
22:659–661. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marcondes FK, Bianchi FJ and Tanno AP:
Determination of the estrous cycle phases of rats: Some helpful
considerations. Braz J Biol. 62:609–614. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H and Edens NK: mRNA expression and
antilipolytic role of phosphodiesterase 4 in rat adipocytes in
vitro. J Lipid Res. 48:1099–1107. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miao ZL, Guo L, Wang YX, Cui R, Yang N,
Huang MQ, Qin WB, Chen J, Li HM, Wang ZN and Wei XC: The
intervention effect of Rosiglitozone in ovarian fibrosis of PCOS
rats. Biomed Environ Sci. 25:46–52. 2012.PubMed/NCBI
|
|
25
|
Liu W, Liu W, Fu Y, Wang Y and Zhang Y:
Bak Foong pills combined with metformin in the treatment of a
polycystic ovarian syndrome rat model. Oncol Lett. 10:1819–1825.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang H, Jung WY, Kang Y, Lee H, Kim A and
Kim BH: Expression of ROR1, pAkt, and pCREB in gastric
adenocarcinoma. Ann Diagn Pathol. 19:330–334. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lafontan M and Berlan M: Fat cell
adrenergic receptors and the control of white and brown fat cell
function. J Lipid Res. 34:1057–1091. 1993.PubMed/NCBI
|
|
28
|
Doseyici S, Mehmetoglu I, Toker A,
Yerlikaya FH and Erbay E: The effects of forskolin and rolipram on
cAMP, cGMP and free fatty acid levels in diet induced obesity.
Biotech Histochem. 89:388–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Snyder PB, Esselstyn JM, Loughney K, Wolda
SL and Florio VA: The role of cyclic nucleotide phosphodiesterases
in the regulation of adipocyte lipolysis. J Lipid Res. 46:494–503.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura J, Okamura N and Kawakami Y:
Augmentation of lipolysis in adipocytes from fed rats, but not from
starved rats, by inhibition of rolipram-sensitive phosphodiesterase
4. Arch Biochem Biophys. 425:106–114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang R, Maratos-Flier E and Flier JS:
Reduced adiposity and high-fat diet-induced adipose inflammation in
mice deficient for phosphodiesterase 4B. Endocrinology.
150:3076–3082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ong WK, Gribble FM, Reimann F, Lynch MJ,
Houslay MD, Baillie GS, Furman BL and Pyne NJ: The role of the
PDE4D cAMP phosphodiesterase in the regulation of glucagon-like
peptide-1 release. Br J Pharmacol. 157:633–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vollert S, Kaessner N, Heuser A, Hanauer
G, Dieckmann A, Knaack D, Kley HP, Beume R and Weiss-Haljiti C: The
glucose-lowering effects of the PDE4 inhibitors roflumilast and
roflumilast-N-oxide in db/db mice. Diabetologia. 55:2779–2788.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Franks S, Stark J and Hardy K: Follicle
dynamics and anovulation in polycystic ovary syndrome. Hum Reprod
Update. 14:367–378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Willis D and Franks S: Insulin action in
human granulosa cells from normal and polycystic ovaries is
mediated by the insulin receptor and not the type-I insulin-like
growth factor receptor. J Clin Endocrinol Metab. 80:3788–3790.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lebbe M and Woodruff TK: Involvement of
androgens in ovarian health and disease. Mol Hum Reprod.
19:828–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Adashi EY, Hsueh AJ and Yen SS: Insulin
enhancement of luteinizing hormone and follicle-stimulating hormone
release by cultured pituitary cells. Endocrinology. 108:1441–1449.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dumesic DA, Akopians AL, Madrigal VK,
Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R,
Schooler TA, et al: Hyperandrogenism accompanies increased
intra-abdominal fat storage in normal weight polycystic ovary
syndrome women. J Clin Endocrinol Metab. 101:4178–4188. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsafriri A, Chun SY, Zhang R, Hsueh AJ and
Conti M: Oocyte maturation involves compartmentalization and
opposing changes of cAMP levels in follicular somatic and germ
cells: Studies using selective phosphodiesterase inhibitors. Dev
Biol. 178:393–402. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thomas RE, Armstrong DT and Gilchrist RB:
Differential effects of specific phosphodiesterase isoenzyme
inhibitors on bovine oocyte meiotic maturation. Dev Biol.
244:215–225. 2002. View Article : Google Scholar : PubMed/NCBI
|
